Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00566904 · ClinicalTrials.gov registry record · Phase 1
New Topical Treatment for Continued Pain After Shingles
A Phase 1 study, sponsored by Biomedical Development Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00566904: Completed Phase 1 study, sponsored by Biomedical Development Corporation.
NCT00566904 is a Phase 1 study that has completed, run by Biomedical Development Corporation. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00566904, a Phase 1 study, has completed, sponsored by Biomedical Development Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Shingles is an outbreak of rash or blisters on the skin that is caused by the same virus that causes chicken pox. Some people experience continued pain even after the shingles rash and blisters have healed; this pain is known as postherpetic neuralgia. The purpose of this study is to evaluate the effectiveness of a new topical treatment for postherpetic neuralgia in adults.
Interventions
- DRUG Epikeia coatings with aspirin
- DRUG Epikeia coatings with lidocaine
- OTHER Epikeia coatings alone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-09 |
| Est. Completion | 2008-09 |
| Phase | Phase 1 |
What the finished NCT00566904 record still lists
NCT00566904 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 3 interventions - of which Epikeia coatings with aspirin is the first listed.
NCT00566904 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00566904 about?
NCT00566904 is a clinical study titled "New Topical Treatment for Continued Pain After Shingles". Shingles is an outbreak of rash or blisters on the skin that is caused by the same virus that causes chicken pox. Some people experience continued pain even after the shingles rash and blisters have healed; this pain is known as postherpetic neuralgia. The purpose of this study is to evaluate the ef...
What is the current status of trial NCT00566904?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2006-09. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00566904?
The interventions under investigation include: Epikeia coatings with aspirin (DRUG), Epikeia coatings with lidocaine (DRUG), Epikeia coatings alone (OTHER).
Who is sponsoring clinical trial NCT00566904?
This trial is sponsored by Biomedical Development Corporation, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00566904's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia